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Atrial natriuretic peptide (ANP) is vasodilatory 
and natriuretic, but whereas increased plasma 
ANP levels occur in spontaneously hypertensive 
rats, their elevated vascular resistance suggests 
inappropriate target tissue responsiveness to ANP. 
This study examines ANP-receptor binding proper-
ties (at 25 °C and 4°C) in cultured vascular aortic 
smooth muscle cells from spontaneously hyperten-
sive (SHR) and control Wistar-Kyoto (WKY) rats. 
[I 1 2 5]-human ANP saturation (0.0625-12.0 nmol) 
profiles were analyzed using nonlinear regression 
(LIGAND). Vascular smooth muscle cells from 
WKY possessed both high affinity (K D 1 0.3 nmol; R! 
33 fmol/10 5 cells) and low affinity (K D 2 15 nmol; R 2 
400 fmol/10 5 cells) binding sites for ANP. In 
contrast, for smooth muscle cells from SHR, two 
receptor forms could not be resolved using identical 
analytical protocols. Parameter estimates at 25 °C 
and 4°C were not different for either SHR or WKY. 
The number of receptors for SHR ( B m a x ~ 100 
fmol/10 5 cells) was lower than the total number of 
receptors for WKY (high plus low affinity ~ 430 
fmol/10 5 cells). The intermediary K D value ( -1 .0 
nmol) for ANP binding in SHR suggests an ANP-
receptor interconversion from high affinity to low 
affinity in smooth muscle cells from SHR. Compe-
tition-binding experiments also revealed a de-
creased affinity for ANP in SHR-derived smooth 
muscle cells. The cyclic GMP response (intracellular 
accumulation and extracellular levels) was de-
creased in SHR smooth muscle cells compared to 
WKY, although this difference was evident only 
after prolonged (one hour) stimulation with ANP. 
Our data indicate a reduced sustained vascular 
responsiveness to ANP in hypertension. Am J 
Hypertens 1989; 2 :32-39 
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Atrial natriuretic peptide (ANP) has potent na-triuretic, aldosterone-renin secretion-inhibi-tory, and vasorelaxing properties that may play a central role in the control of blood vol-
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ume, sodium excretion, and blood pressure, 1" 3 (for re-
views). Receptors for this peptide in vascular tissues 
have been demonstrated for aorta,4 mesenteric and 
renal arteries,5 and for cultured endothelial and smooth 
muscle cells. 6" 9 Studies on the postreceptor actions of 
ANP have shown that ANP activities particulate gua-
nylate cyclase and increases both intracellular and ex-
tracellular cyclic GMP accumulation. 7" 1 2 
Elevated plasma ANP concentrations have been 
demonstrated in disease states associated with an in-
creased cardiopulmonary volume including congestive 
heart failure, 1 3 , 1 4 essential 1 5 , 1 6 and spontaneous hyper-
tension. 1 7 " 2 0 However, in these conditions there is both 
an inappropriate natriuresis and an elevated periph­
eral vascular resistance, to which decreased target tissue 
responsiveness to ANP at receptor or postreceptor sites 
may contribute. S o m e 2 1 " 2 3 but not all 2 4 whole animal 
studies have reported that ANP (bolus administration) 
is more effective and/or potent in eliciting physiological 
responses in spontaneously hypertensive rats (SHR) 
than in Wistar-Kyoto animals (WKY). Similarly in 
humans, natriuretic2 5 and vasodilatory2 6 responsiveness 
to ANP is greater in patients with essential hypertension 
(EHT) than in normotensive subjects (NT). On the other 
hand, ANP produced a less sustained fall in blood pres­
sure in EHT than in NT, 2 5 whereas sustained infusions 
of ANP indicated a lower sensitivity in SHR and WKY. 2 7 
In contrast to whole body studies, investigations using 
isolated thoracic vessels clearly demonstrate reduced 
vasorelaxant responsiveness to ANP in SHR as com­
pared to W K Y . 2 8 - 3 0 Reasons for the general opposite 
nature of hypertensive/normotensive sensitivity differ­
ences between isolated vessel and whole body study 
models are unclear. However, proposals have been 
made that exaggerated physiological responses to ANP 
in hypertensives (for whole body models) may relate to 
their hypertensive arterial2 5 and/or renal 3 1 perfusion 
pressures. 
This study compares the properties of ANP-receptors 
in cultured thoracic aorta smooth muscle cells from SHR 
and WKY under conditions in which in vivo effects re­
lating to differential pressure and circulating levels of 
ANP may be excluded. We have also studied the cyclic 
GMP production response to ANP in these cells. 
MATERIALS AND METHODS 
Materials With the exception of fetal calf serum (Fa-
kola AG, Basel, Switzerland) all tissue culture material 
and chemicals were purchased from Gibco AG, Basel, 
Switzerland. Human a-ANP ( 9 9 - 1 2 6 ) (h-ANP) was 
from Nova Biochem AG, Laufelfingen, Switzerland, 
and [3-(I 1 2 5 )Tyr 1 2 6 ] human a-ANP (99 -126 ) , 2000 C i / 
mmol was from Anawa Laboratories AG, Wangen, 
Switzerland. [3H]cyclic GMP RIA kit was from Amer-
sham International, Amersham, England. All other 
chemicals were of analytical grade and were purchased 
from Merck, Darmstadt, Germany, Fluka AG, Buchs, 
Switzerland or from Sigma Chemical Co., St. Louis, 
MO, USA. 
Animals SHR and WKY rats were obtained from Ma-
doerin AG (Fullinsdorf, Switzerland). Systolic blood 
pressure (mean ± SEM) was measured by the tail cuff 
method and was 215 ± 6 mm Hg for SHR (n = 6), 
130 ± 5 mm Hg for WKY (n = 6). All animals were 
male, aged —20 weeks and weighed 200 g to 250 g. 
Isolation and Culture of Smooth Muscle Cells Pro­
cedures for vascular smooth muscle cell (VSMC) isola­
tion were as described previously by Jones et a l 3 2 and 
Chamley-Campbell et a l 3 3 using matched (SHR ν WKY) 
thoracic aorta sections. Primary cultures were routinely 
passaged for use in experimental regimes, and pheno-
typic characterization was performed exactly as de­
scribed by Jones et al . 3 2 Typically, smooth muscle cells 
from third to sixth passages were used in this study. Cell 
cultures were maintained in minimal essential medium 
(MEM) containing Earles salts, 20 mmol glutamine, 20 
mmol TES-NaOH, 20 mmol HEPES-NaOH (pH 7.3) 
15% fetal calf serum, 100 U/mL penicillin and 100 
U/mL streptomycin and were incubated at 37°C in a 
5 % C 0 2 humidified incubator. For every separate ex­
periment, cell numbers were determined following 
trypsin-dissociation and suspension in Isoton. 
Binding Experiments Binding assays were performed 
in 24-well dishes using procedures described pre­
viously.7 For kinetic binding studies VSMC were incu­
bated at 25°C or at 4°C in the presence of 1.0 nmol 
[I 1 2 5]h-ANP for various time periods; parallel series of 
dishes also contained 0.5 μΜ unlabeled h-ANP for de­
termination of nonspecific binding that was routinely 
less than 10%. Surface bound and internalized [I 1 2 5]h-
ANP were determined as described by Haigler et al . 3 4 
Specific binding is defined as total binding (surface or 
internalized) minus nonspecific binding. Saturation 
binding experiments were conducted for one hour at 
25 °C and 4°C in the presence of various concentrations 
(0 .0625-12 .0 nmol, final) of [I 1 2 5]h-ANP without or 
with 0.5 μΜ unlabeled h-ANP for nonspecific binding. 
Competition experiments were performed in the pres­
ence of 50 pmol [I 1 2 5]h-ANP without or with various 
concentrations ( 1 0 ~ 1 2 - 1 0 ~ 6 mol/L final) of unlabeled 
h-ANP. 
Measurement of Cylic GMP Intracellular cyclic nu­
cleotide levels are controlled not only by cyclase and 
phosphodiesterase activities, but also by egression, such 
that intracellular accumulation represents only a frac­
tion of that synthesized from the onset of stimulation.3 5 
Sustained ANP-induced cyclic GMP egression has been 
demonstrated both in vivo 1 2 and in VSMC cultures. 1 0 
For VSMC from SHR and WKY linearity of cyclic GMP 
intracellular accumulation and extracellular egression in 
response to ANP occurred for up to 15 minutes and 120 
minutes, respectively (data not shown). We have there­
fore measured intra/extracellular cyclic GMP after 
ten-minute and 60-minute treatment with h-ANP. Vas­
cular smooth muscle cells (in 12-well dishes) were incu­
bated at 37°C in 500μ\ PBS containing 0.5 mmol isobu-
tyl-l-methylxanthine in the absence or presence of 
varying concentrations ( 1 0 - 9 - 1 0 - 5 mol/L) h-ANP. Be­
fore preparation of intracellular cyclic GMP extracts7 
aliquots of buffer overlay were withdrawn for measure­
ment of extracellular cyclic GMP. Cyclic GMP was mea­
sured after acetylation 3 6 by radioimmunoassay. 
Data Analysis Saturation binding profiles were indi­
vidually processed by the computer program "EBDA" 3 7 
and then tested for single- and two-site binding models 
using the nonlinear curve fitting program "LIGAND". 3 8 
Application of the LIGAND curve fitting program either 
using experimentally determined nonspecific binding 
(N) or by allowing Ν to float during the fitting process 3 8 
yielded essentially identical parameter estimates. Sig-
moidal log dose-response and competition-binding 
curves for each separate experiment were analyzed 
using a weighted nonlinear regression computer pro­
gram. E D 5 0 is defined as the concentration of ANP re­
quired to elicit a half-maximal response. Statistical anal­
ysis was performed using Student's t test for unpaired 
data. 
RESULTS 
The kinetics of [I 1 2 5]h-ANP binding to VSMC is pre­
sented in Figure 1. For VSMC from both SHR and WKY 
equilibrium binding was reached after a 30- to 60-min-
ute incubation at either 25 °C or 4°C. Within each 
VSMC type surface bound [I 1 2 5]h-ANP at equilibrium 
was not significantly different between experiments 
performed at 25 °C and 4°C. At 25 °C, but not at 4°C, 
both SHR- and WKY-derived cells internalized 7% of 
total ligand bound. 
Binding of [I 1 2 5]h-ANP, at 25 °C, to VSMC was com­
petitive (Figure 2). The concentration of h-ANP re­
quired to half-maximally displace [I 1 2 5]h-ANP was 
— six-fold greater (P < .01) in SHR-derived cells 
(1.72 ± 0.4 nmol, η = 4) than that in WKY-derived cells 
(0.27 ± 0.08, η = 4). Similar differences were evident 
for experiments performed at 4°C and competition pro-
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F I G U R E 2. Competition binding of [I125]h-ANP to cultured 
aortic smooth muscle cells. VSMC from SHR (Φ) and WKY (O) were 
incubated for one hour at 25°C with 50 pmol [I125]h-ANP and 
varying concentrations of unlabeled h-ANP as described in the 
Materials and Methods section. Bound ligand (B) is expressed as 
the percentage of that bound (B0) in the absence of unlabeled 
h-ANP (B0 taken as 100%). Values are mean ± SEM from seven 
separate experiments. 
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F I G U R E 1. [I125]h-ANP binding kinetics in cultured aortic 
smooth muscle cells. VSMC from SHR (closed symbols) and WKY 
(open symbols) were incubated with 1.0 nmol [I125] h-ANP for the 
indicated times at 25°C (solid lines) and 4°C (dashed lines). 
Specifically surface-bound (Ο,Φ) and internalized (A,A) ligand 
were determined as detailed in the Materials and Methods section. 
Data (mean of triplicate determinations) are from a single typical 
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F I G U R E 3. Saturable binding of [I125]h-ANP to culture aortic 
smooth muscle cells. Saturation binding was performed at 4° Con 
VSMC from SHR (panel Α, Φ) and WKY (panel B, A) as described in 
the Materials and Methods section. Scatchard plots for presented 
binding data are inset. Data (specific binding) are representative of 
single typical experiments for SHR and WKY, and each point is the 
mean of duplicate determinations. Cell numbers of SHR and WKY 
were 7.5 Χ 105 and 5.5 X 105, respectively. Final LIGAND pa­
rameter estimates for all experiments at 25°C and 4°C are pre­
sented in Table 1. 
T A B L E 1. P A R A M E T E R E S T I M A T E S F O R [ I 1 2 5 ] h - A N P B I N D I N G T O V A S C U L A R A O R T I C S M O O T H 
M U S C L E C E L L S F R O M S H R A N D W K Y 
O n e - S i t e M o d e l i n g 
A n i m a l B i n d i n g ( ° C ) K D (nmol ) B m a x ( f m o l / 1 0 5 cells) 
W K Y (n = 7) 4 ° 0 . 3 0 + 0 . 1 0 3 8 . 0 ± 9 . 8 
2 5 ° 0 . 3 8 ± 0 . 0 8 3 6 . 8 ± 1 0 . 2 
S H R (n = 7) 4 ° 1 .01 ± 0 . 2 9 * 1 0 2 . 5 ± 2 3 . 4 * 
2 5 ° 0 . 9 2 ± 0 . 1 2 * 1 0 1 . 4 ± 2 0 . 0 * 
T w o - S i t e M o d e l i n g 
K D I K D 2 R t R 2 
(nmol) ( f m o l / 1 0 5 cells) 
W K Y (n = 14 ) 0 . 3 3 ± 0 . 0 8 1 4 . 8 ± 2 . 1 3 2 . 9 ± 6 .6 4 0 3 . 2 ± 3 6 . 1 
Binding parameters were obtained from "LIGAND" data analysis. 
For one-site modeling KD and Bmax represent the dissociation constant and maximum number of binding sites respectively. 
* indicates significant differences (P < .01) between SHR and WKY for binding at 4°C or 25°C. 
For two-site modelling KD1 and KD2 are dissociation constants and R2 and R2 are numbers of sites with high and low affinity respectively. 
Parameter estimates from 25°C and 4°C binding experiments were similar, thus combined values are presented. 
All values are given as mean ± SEM where η = number of separate experiments. 
files using rat-ANP were essentially identical to those 
obtained with h-ANP (data not shown). 
Equilibrium binding of [I 1 2 5]h-ANP to SHR and WKY 
VSMC was saturable at both 4°C (Figure 3) and 25°C 
(profiles not shown and not significantly different from 
data obtained at 4°C). For VSMC from WKY, saturation 
profiles demonstrated deviation from a simple bimole-
cular binding isotherm (Figure 3B). Scatchard-trans-
formed data for WKY was curvilinear (Figure 3B, inset) 
and Hill analysis yielded a coefficient significantly less 
than unity (0.59 ± 0.07, η = 7). In contrast, for SHR-de-
rived VSMC (Figure 3A, inset) Scatchard transforma­
tion yielded an apparently linear plot, whereas the Hill 
coefficient approximated unity (0.94 ± 0.02, η = 7). 
In the LIGAND analysis for a single site model both 
the maximum number of binding sites (B m a x ) and the 
dissociation constant (KD) were greater (P < .01) for 
VSMC from SHR than VSMC from WKY (Table 1). 
These differences were evident at both 25 °C and 4°C. 
However, LIGAND analysis for a two-site model im­
proved the goodness of fit (P at least .05) for VSMC from 
WKY and enabled resolution of high (K D 1 ~ 1 0 " 1 0 mol) 
and low (K D 2 ~ 10~ 8 mol) affinity binding sites could be 
resolved, and the number of high affinity sites (Table 1). 
For VSMC from SHR, in only two out of the fourteen 
experiments (25 °C and 4°C) was a significantly im­
proved data-fit obtained (data not shown). The total 
number of binding sites (R1 plus R 2 , from two-site analy­
sis) for VSMC from WKY (428 ± 29.3 fmol/10 5 cells, 
25°C and 4°C data pooled (n = 14)) was greater (P < 
.01) than the number of sites (101.9 ± 21.2 fmol /10 5 
cells; B m a x from one-site analysis, 25°C and 4°C data 
pooled (n = 10) fro VSMC from SHR. 
Spontaneously hypertensive rat- and WKY-derived 
VSMC were examined for their physiological respon­
siveness to h-ANP in terms of both intra- and extracel­
lular cyclic GMP accumulation (Figures 4 and 5). Basal 
levels of intracellular cyclic GMP were not significantly 
different between SHR and WKY. After a ten-minute 
incubation with h-ANP, neither levels of intracellular 
cyclic GMP accumulated (Figure 4A) nor sensitivity 
(ED 5 0) to h-ANP (Table 2) differed between SHR and 
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F I G U R E 4. Intracellular cyclic GMP accumulation in response 
to h-ANP. VSMC from WKY(A) and SHR (A) were treated at 37°C 
with varying concentrations of h-ANP (in the presence of 0.5 mmol 
isobutylmethylxanthine) for either10 minutes (panel A, η = 11) or 
60 min (panel B,n = 5). Intracellular cyclic GMP was quantitated 
as described in the Materials and Methods section. Data points are 
mean ± SD and ED50 values are given in Table 2. Asterisks indi­
cate significant differences between SHR and WKY; *P < .05, 
**P <.01. 
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F I G U R E 5. Extracellular cyclic GMP accumulation in response 
to h-ANP. Cells from WKY (O) and SHR (Φ) were treated at37°C 
with h-ANP (in the presence of isobutylmethylxanthine) for 10 
minutes (panel A) or 60 minutes (panel B). Cyclic GMP in the 
extracellular medium overlay was determined as described in the 
Materials and Methods section. Data are mean ± SD where n = 5 
for both time periods. ED50 values are given in Table 2. Asterisks 
indicate significant (P < .01) differences between SHR and WKY. 
WKY. After a 60-minute exposure to h-ANP, levels of 
intracellular cyclic GMP were significantly higher (Fig­
ure 4B) and the E D 5 0 for h-ANP significantly lower 
(Table 1) in WKY than in SHR. While stimulated cyclic 
GMP levels in WKY were sustained with prolonged 
hormone treatment, the apparent accumulation of in­
tracellular cyclic GMP by SHR was markedly lower after 
60 minutes relative to that at ten minutes (Figure 4). 
After a ten-minute incubation in the absence or pres­
ence of h-ANP, extracellular cyclic GMP levels were not 
significantly different between WKY- and SHR-derived 
cells, although there was a trend for greater egress of this 
cyclic nucleotide in WKY (Figure 5 A). However, after a 
60-minute incubation, both basal and h-ANP stimu­
lated levels of extracellular cyclic GMP were signifi­
cantly greater for WKY-derived cells than SHR (Figure 
5B). The E D 5 0 for h-ANP associated cyclic GMP egress 
was comparable between SHR and WKY in short-term 
(ten minute) incubations, but was significantly lower for 
WKY-derived cells than SHR when calculated after 
long-term (60 minute) incubations (Table 2). 
DISCUSSION 
This study demonstrates differences in both the number 
and affinity of ANP-receptors on cultured thoracic aorta 
VSMC from SHR and WKY. In addition, the cyclic GMP 
response to ANP is decreased in SHR-derived VSMC 
in terms of their ability to increase either intracellular or 
extracellular cyclic GMP levels. 
T A B L E 2. C Y C L I C G M P R E S P O N S E T O h - A N P I N 
S M O O T H M U S C L E C E L L S F R O M S H R A N D W K Y 
EDgo (nmol ) for A N P 
I n c u b a t i o n Int race l lu lar E x t r a c e l l u l a r 
A n i m a l (min) cycl ic G M P cycl ic G M P 
W K Y 10 9 0 ± 15 (11 ) 1 0 0 ± 2 0 (5) 
S H R 10 8 5 ± 2 0 ( 1 1 ) N S 9 0 ± 10 ( 5 ) N S 
W K Y 6 0 2 9 ± 19 (5) 3 5 ± 1 7 ( 5 ) 
S H R 6 0 8 0 ± 1 7 ( 5 ) t 7 3 ± 2 0 (5 )* 
ED50 values (mean ± SD) were obtained from experiments presented in 
Figure 5. 
Number in parentheses indicates the number of separate experiments 
performed. 
* Ρ < .05. 
t Ρ < .01 and indicates significance between SHR and WKY (60-min 
incubation). 
Abbreviation: NS, no significant difference between SHR and WKY (10-
min incubation). 
Analysis of our data for [I 1 2 5]h-ANP binding accord­
ing to a single-site model yielded parameter estimates 
(KD 0 . 3 -1 .0 nmol, B m a x 3 0 - 1 0 0 fmol /10 5 cells) that are 
comparable to those previously reported (KD 0 . 6 - 2 . 1 
nmol, B m a x 1 8 - 8 0 fmol /10 5 cells) for VSMC. 7 " 9 Such 
analysis indicated that in VSMC from SHR, the affinity 
for ANP was decreased and the B ^ was increased rela­
tive to WKY. These findings agree with two previous 
reports comparing ANP-binding on cultured aortic 
VSMC from SHR and WKY. 1 9 ' 3 9 However, other studies 
using similar binding techniques have reported a de­
creased B m a x in aortic smooth muscle tissue 2 0 and kid­
ney, 4 0 , 4 1 for SHR with unaltered 2 0 or increased 4 1 affini­
ties for ANP. Using autoradiographic techniques B ^ 
and affinity for ANP were decreased in brain from 
SHR, 4 2 , 4 3 whereas the B m a x was unaltered in adrenals 
and kidney. 4 3 The reasons for these discrepant observa­
tions are unclear, but may relate to variations in tissue 
selection, age, and methodologies. 
Our observation of two ANP-receptor classes on 
VSMC (K D 1 — 0.3 nmol, K D 2 ~ 15 nmol) has also been 
made for bovine adrenal zona glomerulosa (K D 1 — 0.04 
nmol, K D 2 — 6 nmol). 4 4 Because binding parameter esti­
mates obtained at 25°C and 4°C were not significantly 
different within either SHR- or WKY-derived VSMC 
and both cell strains internalized [I 1 2 5]h-ANP to the 
same extent, our binding parameters are a measure of 
cell-surface bound [I 1 2 5]h-ANP. We can thus exclude the 
possibility that differences between WKY (two-site 
model) and SHR (one-site model) are due to an addi­
tional internal component in WKY only. The lack of 
demonstration of two ANP-receptor classes (using satu­
ration-binding methodology) in previous studies on 
smooth muscle cells may be due to insufficient data 
representation at higher (— 4 nmol) ANP concentrations 
or to inadequate curve-fitting analysis. 
Our inability to reproducibly resolve two receptor 
classes on SHR-VSMC may be due to their very low 
proportion of high affinity receptors ( ~ 3 % as assessed 
from the two experiments in which a significant im­
provement of fit for two-site LIGAND analysis was ob­
tained). This, together with their apparent decreased 
affinity for ANP suggests that in SHR, ANP-receptors 
are predominantly in the low affinity form. Since their 
K D (~ 1.0 nmol) is one order of magnitude lower than the 
expected value (—15 nmol) if all receptors were to exist 
in the low affinity form, the total conversion of receptors 
from the high to the low affinity type does not appar­
ently occur in SHR. Moreover, whereas single site anal­
ysis indicated a greater receptor number in SHR than 
WKY, the B m a x for SHR (~ 100 fmol /10 5 cells) was lower 
than the total receptor number obtained for WKY (Rx + 
R2 ~ 400 fmol /10 5 cells) with more appropriate two-
site analysis. This may be a further reflection of incom­
plete receptor-interconversion, in which case 
values from one-site Scatchard analysis, albeit the best 
fit for SHR, represent an underestimation of the true 
total receptor number. 
Interpretation of our binding data in term of receptor-
interconversion remains speculative however, and is 
not the only possible explanation for our findings. 
Down-regulation of ANP-receptors on VSMC 4 5 re­
quires prolonged exposure to hormone and is revers­
ible. 4 6 , 4 7 Thus, although plasma ANP levels are elevated 
in S H R , 1 7 - 2 0 ANP is not present in culture media (un­
published observation) and culturing conditions thus 
favor reversibility of any prior in vivo down-regula­
tion. Alternatively, receptor desensitization through co-
valent receptor modification, for example by cyclic 
AMP-dependent protein kinase or protein kinase C 4 7 / 4 8 
may also be considered because in hypertension, abnor­
malities in both cyclic AMP and phosphoinositide me­
tabolism occur. Whatever the factors/mechanisms re­
sponsible for alterations of ANP-receptor properties in 
SHR-VSMC, we can assume they are inherent, because 
our observations were made in passaged cell cultures. 
In order to assess the physiological relevance of alter­
ations in ANP-receptor binding properties, we exam­
ined the cyclic GMP response of VSMC from SHR and 
WKY. A striking observation for both VSMC strains, 
and one that has been previously made in a variety of 
tissues including smooth muscle 5 , 7 " 9 is that the E D 5 0 
values for intracellular and extracellular cyclic GMP re­
sponses to ANP are at least one order of magnitude 
greater than receptor K D values. This problem of dissoci­
ation between ANP-receptor binding and concomitant 
cyclic GMP response remains to be resolved. Undoubt­
edly particulate guanylate cyclase activation/cyclic 
GMP formation are involved in ANF-elicited 
vasodilatation,8"1 1 but changes in cyclic GMP need not 
necessarily reflect the primary/sole cellular manifesta­
tion of ANP-receptor-mediated action. It is conceivable 
that cofactors may be required for the cyclic GMP re­
sponse and that alternative/synergistic second-messen­
ger (receptor-coupled) pathways for ANP exist.7 
Previous comparative studies (SHR ν WKY) on intra­
cellular cyclic GMP accumulation in response to ANP 
have reported either decreased levels in VSMC from 
SHR, 3 9 or increased levels in smooth muscle and adrenal 
capsular cell suspensions. 2 0 In this study, differences in 
the cyclic GMP response to ANP between SHR- and 
WKY-derived VSMC emerged only after prolonged ex­
posure to ANP, whereby WKY exhibited a greater abil­
ity to persistently accumulate intracellular cyclic GMP 
than SHR. This may account for the leftward shift (de­
creased apparent ED 5 0 ) in WKY dose profiles after pro­
longed treatment. These data may be relevant to obser­
vations of less sustained physiological responsiveness to 
ANP in EHT 2 5 and in SHR. 2 7 
That extracellular cyclic GMP levels were lower for 
SHR-derived cells than those from WKY probably re­
flects the attenuation of sustained intracellular cyclic 
GMP accumulation in SHR. In addition the capacity for 
cyclic GMP extrusion may be decreased in SHR as evi­
denced by their significantly lower extracellular cyclic 
GMP levels (relative to WKY at 60 minutes) even in the 
absence of stimulation by ANP. The biological conse­
quences of cyclic GMP egression, and the relevance to 
hypertension of alterations in this process remain to be 
determined. 
In physiological terms, the findings reported herein 
may be interpreted to suggest that aortic VSMC from 
SHR exhibit decreased responsiveness to ANP, and/or 
the biological effectiveness of ANP is lowered in SHR. 
While we ourselves have no direct physiological data to 
support these conclusions, thoracic aorta 2 9 , 3 0 and mes­
enteric resistance 2 8 vessels from SHR have been demon­
strated to be significantly less sensitive to the relaxing 
actions of ANP. Therefore, altered ANP binding and 
transduction processes thereof in target tissues may be 
relevant to hypertension. 
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